The value of spirometry and exercise challenge test to diagnose and monitor children with asthma

Respirology Case Reports

Early View (Online Version of Record published before inclusion in an issue)

1. Lara S. van den Wijngaart^*, 
2. Jolt Roukema and
3. Peter J.F.M. Merkus

Article first published online: 3 FEB 2015

DOI: 10.1002/rcr2.92

Abstract

Asthma is defined as a chronic inflammatory disease of the airways with characteristic symptoms including recurrent episodes of wheezing, breathlessness, chest tightness, and coughing.

Respiratory disease and respiratory physiology: Putting lung function into perspective: Paediatric asthma

Invited Review Series: Respiratory Disease: Using Lung Function Measurements to Greater Advantage

You have free access to this content

Lara S. van den Wijngaart^*, 

Jolt Roukema and

Peter J.F.M. Merkus

Article first published online: 3 FEB 2015 DOI: 10.1111/resp.12480

View Full Article (HTML) Enhanced Article (HTML) Get PDF (275K)

Abstract

Dealing with paediatric asthma in daily practice, we are mostly interested in the airway function: the hallmark of asthma is the variability of airway patency.

Influence of the route of exposure and the matrix on the sensitization potency of a major cows’ milk allergen

Brief communication

Published: 28 January 2015

Sophie Wavrin¹, Herve Bernard¹, Jean-Michel Wal² and Karine Adel-Patient^1*

Clinical and Translational Allergy 2015, 5:3  doi:10.1186/s13601-015-0047-x

Abstract (provisional)

Background

Allergic sensitisation to food may occur through non-gastrointestinal routes such as via skin or lung. We recently demonstrated in mice that cutaneous or respiratory pre-exposures to peanut proteins on intact epithelia induce a Th2 priming and allow subsequent oral sensitization without the use of adjuvant. We then aimed to assess the impact of a similar pattern of exposure to another relevant food allergen, cows´ milk.

Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide

ORIGINAL RESEARCH

• Abstract
• Fulltext
• Metrics

Authors Price D, Kaplan A, Jones R, Freeman D, Burden A, Gould S, von Ziegenweidt J, Ali M, King C, Thomas M

Published Date January 2015 Volume 2015:8 Pages 1—13

DOI http://dx.doi.org/10.2147/JAA.S76639

Received 30 October 2014, Accepted 20 November 2014, Published 14 January 2015

Approved for publication by Dr Amrita Dosanjh

David Price,^1,2 Alan Kaplan,³ Rupert Jones,⁴ Daryl Freeman,⁵ Anne Burden,² Shuna Gould,² Julie von Ziegenweidt,² Muzammil Ali,² Christine King,² Mike Thomas^6
1Academic Centre of Primary Care, University of Aberdeen, Aberdeen, ²Research in Real-Life, Cambridge, UK; ³Family Physician Airways Group of Canada, Richmond Hill, ON, Canada; ⁴Centre for Clinical Trials and Health Research, Plymouth University, Plymouth, ⁵Norfolk Community Health and Care NHS Trust, Norwich, ⁶Primary Care Research, University of Southhampton, Southhampton, UK

Background: Randomized controlled trials indicate that addition of a long-acting muscarinic antagonist (LAMA) such as tiotropium may improve asthma control and reduce exacerbation risk in patients with poorly controlled asthma, but broader clinical studies are needed to investigate the effectiveness of LAMA in real-life asthma care.

Clinical similarities among bradykinin-mediated and mast cell-mediated subtypes of non-hereditary angioedema: a retrospective study

Research

Karlijn J G Schulkes^1†, Mignon T Van den Elzen^1*†, Erik C Hack¹², Henderikus G Otten²,Carla A F M Bruijnzeel-Koomen¹ and André C Knulst¹

Clinical and Translational Allergy 2015, 5:5  doi:10.1186/s13601-015-0049-8

Published: 4 February 2015

Abstract (provisional)

BackgroundNon-hereditary angioedema (non-HAE) is characterized by local swelling due to self-limiting, subcutaneous or submucosal extravasation of fluid, and can be divided into three subtypes.

Allergic drug reactions traced to single protein

Research from UAlberta and Johns Hopkins University points to new strategy to reduce allergic responses to multiple medications.

Priyanka Pundir and Marianna Kulka in the lab

Every day in hospitals around the world, patients suffer painful allergic reactions to the medicines they are given. The reactions, known as pseudo-allergies, often cause patients to endure itchiness, swelling and rashes as an unwanted part of their treatment plan. The reactions can be so severe they may stop patients from taking their needed medications and sometimes can even prove fatal. It’s never been shown conclusively what triggers these allergic reactions—until now.

Clinical Practice Guideline: Allergic Rhinitis

Michael D. Seidman, MD1, Richard K. Gurgel, MD2, Sandra Y. Lin, MD3, Seth R. Schwartz, MD, MPH4, Fuad M. Baroody, MD5, James R. Bonner, MD6, Douglas E. Dawson, MD7, Mark S. Dykewicz, MD8 , Jesse M. Hackell, MD9, Joseph K. Han, MD10, Stacey L. Ishman, MD, MPH11, Helene J. Krouse, PhD, ANP-BC, CORLN12, Sonya Malekzadeh, MD13, James (Whit) W. Mims, MD14, Folashade S. Omole, MD15, William D. Reddy, LAc, DiplAc16, Dana V. Wallace, MD17, Sandra A. Walsh18, Barbara E. Warren, PsyD, MEd18, Meghan N. Wilson, MD19, Lorraine C. Nnacheta, MPH20

SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms

February 2015 Volume 114, Issue 2, Pages 134–140.e1

Holger Mosbech, MD

, 

G. Walter Canonica, MD

, 

Vibeke Backer, MD

, 

Frederic de Blay, MD

, 

Ludger Klimek, MD

,

Louise Broge, PhD

, 

Christian Ljørring, MSc

Open Access

DOI: http://dx.doi.org/10.1016/j.anai.2014.11.015

Open access funded by the Author(s)

Article Info